KalVista Pharmaceuticals, Inc.
KALVDelisted Jun 11, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001348911
KalVista Pharmaceuticals, Inc. was delisted on Jun 11, 2026; its insiders filed their last Form 4 on Jun 11, 2026; 184 institutions reported holding it in 13F filings for Q1 2026, worth $1.39B in total; no superinvestor held it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 184
- Q1 2026, +25 vs. previous quarter
- 13F value
- $1.39B
- Reported value at the end of Q1 2026
- Superinvestors holding
- 0
- At the end of Q1 2026
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$183.4M
- No comparable prior period
- Free cash flow, FY2025
- -$153.3M
- No comparable prior period
- Revenue, Q1 FY2026
- $40.9M
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date May 29, 2026.
- Short interest
- 6.84M
- Shares sold short
- Change
- −5.21M
- −43.2% vs. previous
- Days to cover
- 1.97
- At average daily volume
Superinvestors holding KALV, Q1 2026
Go to the superinvestors tabNo superinvestor reported holding KALV at the end of Q1 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by KalVista Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 29, 2026 (view filing) | May 27 | 2 days | Yea ChristopherCHIEF DEVELOPMENT OFFICER | SSale | −33.8K | $26.78 | −$905.2K | −12.8%229.9K after | |
| May 27, 2026 (view filing) | May 26 | 1 day | Audhya Paul K.CHIEF MEDICAL OFFICER | SSale | −2.24K | $26.78 | −$60.0K | −1.5%150.3K after | |
| May 27, 2026 (view filing) | May 26 | 1 day | Sweeny NicoleChief Commercial Officer | SSale | −1.49K | $26.78 | −$39.9K | −2.4%59.3K after | |
| May 27, 2026 (view filing) | May 26 | 1 day | Yea ChristopherCHIEF DEVELOPMENT OFFICER | SSale | −1.97K | $26.78 | −$52.6K | −0.8%229.9K after | |
| May 26, 2026 (view filing) | May 22 | 4 days | Audhya Paul K.CHIEF MEDICAL OFFICER | SSale | −2.69K | $26.78 | −$71.9K | −1.8%147.5K after | |
| May 26, 2026 (view filing) | May 22 | 4 days | Sweeny NicoleChief Commercial Officer | SSale | −1.86K | $26.78 | −$49.8K | −3.2%55.8K after | |
| May 26, 2026 (view filing) | May 22 | 4 days | Piekos BrianChief Financial Officer | SSale | −1.49K | $26.78 | −$39.9K | −6.4%21.7K after | |
| May 26, 2026 (view filing) | May 22 | 4 days | Yea ChristopherCHIEF DEVELOPMENT OFFICER | SSale | −2.36K | $26.78 | −$63.1K | −1.0%228.8K after | |
| May 26, 2026 (view filing) | May 22 | 4 days | Palleiko Benjamin LCHIEF EXECUTIVE OFFICER | SSale | −10.9K | $26.78 | −$292.6K | −2.2%480.0K after | |
| May 19, 2026 (view filing) | May 18 | 1 day | Audhya Paul K.CHIEF MEDICAL OFFICER | SSale | −1.03K | $26.76 | −$27.6K | −0.7%143.9K after |
Top 10 13F holders, Q1 2026
See all 184 holdersThe largest institutional positions in KalVista Pharmaceuticals, Inc. at the end of Q1 2026; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| VR Adviser, LLC | 6,474,485 | $130.3M | 4.86% | −254,500−3.8% | Reduced |
| Frazier Life Sciences Management, L.P. | 4,961,108 | $99.9M | 2.57% | −78,759−1.6% | Reduced |
| Suvretta Capital Management, LLC | 4,768,712 | $96.0M | 2.60% | 00.0% | Unchanged |
| Tang Capital Management LLC | 4,573,530 | $92.1M | 4.68% | 00.0% | Unchanged |
| BlackRock, Inc. | 3,795,897 | $76.4M | 0.00% | +41,749+1.1% | Added |
| Silverarc Capital Management, LLC | 2,876,407 | $57.9M | 6.82% | +449,289+18.5% | Added |
| Capital World Investors | 2,808,583 | $56.5M | 0.01% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 2,136,940 | $43.0M | 0.07% | −146,826−6.4% | Reduced |
| State Street Corp | 1,955,844 | $39.4M | 0.00% | +44,153+2.3% | Added |
| Millennium Management LLC | 1,912,146 | $38.5M | 0.03% | −984,520−34.0% | Reduced |
Holders of 5% or more of KALV
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of KalVista Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Capital World Investors | 13G/A | 6.40%3.18M shares | – | Nov 13, 20242 filings | May 13, 2025 | SEC |
| Silverarc Capital Management, LLC | 13G | 5.60%2.88M shares | New | May 13, 20261 filing | May 13, 2026 | SEC |
Politician trades
All politician trades in KALV1 member of Congress reported 1 trade in KalVista Pharmaceuticals, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Jan 20, 2023 |  Chris Jacobs House · NY | Buy | $1K-$15K |
House · NY · Jan 20, 2023
Buy$1K-$15K